Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)
Interim data expected in the second half of 2019
NEW YORK and CLEVELAND, May 14, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company has completed dosing cohort 1 and treated the first patient in cohort 2 in an ongoing Phase 1/2 clinical trial evaluating ABO-101, its novel one-time gene therapy for Sanfilippo syndrome type B (MPS IIIB). The Company expects to report interim data from the trial in the second half of 2019.
“We believe that ABO-101 can help address the underlying lysosomal enzyme deficiency that ultimately results in progressive cell damage and neurodevelopmental and physical decline in children with MPS IIIB,” said João Siffert, M.D., Chief Executive Officer. “The product safety profile to date and clear evidence of biological activity provide support for advancing this clinical trial to the second cohort. This multicenter study is made possible by our close collaborations with expert academic investigators and the participants who enrolled to date. We look forward to presenting interim data in the second half of this year.”
The Phase 1/2 trial is a two-year, open-label, dose-escalation, global clinical trial in patients diagnosed with MPS IIIB who are older than six months of age and have a minimum cognitive Development Quotient of 60 or above. The study is expected to include up to nine patients and is designed to evaluate two doses of ABO-101 with cohort 1 receiving 2 X 1013 vg/kg and cohort 2 receiving 5 X 1013 vg/kg. ABO-101 is delivered using NAV® AAV9 technology via a one-time intravenous infusion. The primary endpoint of the study is to assess neurodevelopment and safety, with multiple secondary and exploratory endpoints including neurocognitive and behavior evaluations, quality of life, enzyme activity in cerebrospinal fluid (CSF) and plasma, biomarkers in CSF, plasma and urine, and brain and liver volume.
Abeona is enrolling eligible patients with MPS IIIB at sites in the U.S. and Spain and expects to activate additional sites globally this year to accelerate enrollment. Additional information about the study is available at AbeonaTrials.com and ClinicalTrials.gov (NCT03315182).
About Sanfilippo syndrome type B (MPS IIIB)
Sanfilippo syndrome type B (MPS IIIB) is a rare and fatal lysosomal storage disease with no approved therapy that primarily affects the central nervous system and is characterized by rapid neurodevelopmental and physical decline. Children with MPS IIIB present with progressive language and cognitive decline and behavioral abnormalities. Other symptoms include sleep problems and frequent ear infections. Additionally, distinctive signs such as facial features with thick eyebrows or a unibrow, full lips and excessive body hair for one’s age and liver/spleen enlargement are also present. The underlying cause of MPS IIIB is a deficiency in the NAGLU enzyme responsible for breaking down glycosaminoglycans, which accumulate throughout the body resulting in rapid decline associated with the disorder.
ABO-101 is a novel gene therapy in Phase 1/2 development for Sanfilippo syndrome type B (MPS IIIB), a rare lysosomal storage disease with no approved therapy that primarily affects the central nervous system (CNS). ABO-101 is dosed in a one-time intravenous infusion using the NAV® AAV9 vector to deliver a functional copy of the NAGLU gene to cells of the CNS and peripheral tissues. The therapy is designed to address the underlying NAGLU enzyme deficiency responsible for abnormal accumulation of glycosaminoglycans in the brain and throughout the body that results in progressive cell damage and neurodevelopmental and physical decline. In the U.S., Abeona holds Fast Track and Rare Pediatric Disease designations for ABO-101 and Orphan Drug designation in both the U.S. and EU.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Company’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel NAV® AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively. The Company’s portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Its preclinical assets include ABO-401, which uses the novel AIM™ AAV vector platform to address all mutations of cystic fibrosis. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates and is the only company with Regenerative Medicine Advanced Therapy designation for two candidates (EB-101 and ABO-102). For more information, visit www.abeonatherapeutics.com.
Forward Looking Statement
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements regarding our pipeline including the potential for ABO-101 in the treatment of Sanfilippo syndrome type B, including the results of clinical studies, the ability to present interim data, the ability to continue to enroll patients in clinical studies, the ability to obtain regulatory marketing approvals, and the company’s goals and objectives. We have attempted to identify forward looking statements by such terminology as “may,” will,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” and similar expressions.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to: continued interest in our rare disease portfolio, our ability to initiate and enroll patients in clinical trials, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks as may be detailed from time to time in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Senior Director, Investor Relations
+1 (646) 813-4710
Director, Corporate Communications
+1 (718) 344-5843
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Maha Energy AB (publ) (“Maha” or the “Company”) Announces Filing of Second Quarter Report and Live Webcast26.8.2019 01:00:00 CEST | Press release
Maha Energy AB (publ) Strandvagen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm 26 August 2019 Maha Energy AB Announces Filing of Second Quarter Report & Live Webcast Maha Energy AB (publ) (“Maha” or the “Company”) is pleased to announce its second quarter results. The report is attached to this press release and available on the Company’s website at www.mahaenergy.ca Second Quarter 2019 Daily oil & gas production for Q2 2019 averaged 2,739 BOEPD (Q2 2018: 1,429 BOEPD). Revenue of USD 14.1 million (Q2 2018: USD 7.9 million) Operating netback of USD 10.7 million or USD 43.30 per BOE (Q2 2018: USD 5.1 million or USD 39.22 per BOE) EBITDA of USD 9.2 million (Q2 2018: USD 4.0 million) Net result of USD 6.2 million (Q2 2018: USD 1.9 million) Basic and diluted Earnings per share of USD 0.06 (Q2 2018: USD 0.02) Six Months Ended 30 June 2019 Daily oil & gas production for H1 2019 2,704 BOEPD (H1 2018: 1,595 BOEPD). Revenue of USD 25.8 million (H1 2018: USD 16.5 million) Oper
Cargotec appoints Päivi Koivisto as Vice President, Sustainability25.8.2019 09:00:00 CEST | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 25 AUGUST 2019 AT 10:00 AM (EEST) Cargotec appoints Päivi Koivisto (M.Sc. Env. Tech., eMBA) as Vice President, Sustainability as of 23 September 2019. She will be responsible for Cargotec's corporate Sustainability function. Koivisto joins Cargotec from UPM Communications Papers where she worked as Director, Sustainability. Päivi Koivisto reports to Cargotec's SVP Communications Carina Geber-Teir. "At Cargotec, we firmly believe that a profitable and sustainable business requires ethical and sustainable ways of working. Päivi has a solid track record from an industry where these issues have been developed with determination for years. I am pleased to welcome Päivi to Cargotec. Her passion for and expertise in sustainability makes her a perfect fit to drive Cargotec’s sustainability actions to an increasingly higher level," says Carina Geber-Teir. For more information, please contact: Carina Geber-Teir, SVP Communications, Cargotec, carina.geber-teir
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration23.8.2019 22:01:00 CEST | Press release
Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on 14 July 2019. This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $3.95 billion by Gilead to Galapagos. In addition, Gilead has made an equity investment in Galapagos of approximately $1.1 billion (or approximately €960 million) by subscribing for new shares at a price of €140.59 per share, including issuance premium. As a result, Gilead now owns 13,589,686 ordinary shares of Galapagos, representing approximately 22 percent of the currently outsta
EVS Broadcast Equipment strikes major deal with NEP to upgrade their US production activities23.8.2019 18:00:00 CEST | Press release
Publication on August 23 2019, 06:00 P.M. CET Regulated information – Privileged information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS STRIKES MAJOR DEAL WITH NEP TO UPGRADE THEIR US PRODUCTION ACTIVITIES EVS Broadcast Equipment, the leading provider of live production solutions, today announces that NEP is investing over $8m to deploy the next generation EVS live video production server as part of their US inventory. Liège, Belgium, August 23, 2019 EVS, the leading provider of live production solutions, has been selected by NEP, an international production company serving live broadcasting throughout the world, to deliver a major upgrade and upscale of their production facilities. The deal represents the acquisition of EVS’ XT-VIA next-generation live production servers, as well as the deployment of LSM replay controllers, IPDirector content management solutions and other infrastructure systems. All new systems will be installe
Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 201923.8.2019 17:35:00 CEST | Press release
Allschwil, Switzerland – August 23, 2019 Idorsia Ltd (SIX: IDIA) today announced that data from Phase 2 studies with aprocitentan, a new dual endothelin receptor antagonist, and selatogrel, a highly-selective P2Y12 receptor antagonist, will be shared during the European Society of Cardiology (ESC) Congress 2019 in Paris, France. Idorsia’s aprocitentan An oral presentation entitled "Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension", will be part of the "Drug treatment in hypertension - New insights" session with a focused discussion with the lead author, Dr Parisa Danaietash from Idorsia, at 09:54 on August 31, 2019. The abstract can be found online. Idorsia’s selatogrel An oral presentation entitled "Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients", will be part of th
Millicom - H1 2019 Consolidated Financial Statements23.8.2019 16:53:00 CEST | Press release
Millicom’s H1 2019 Consolidated Financial Statements Luxembourg, August 23, 2019— Millicom, a leading provider of cable and mobile services operating under the TIGO brand in Latin America, has published its H1 2019 consolidated financial statements. Contents include: • Management Report • Responsibility Statement • Review Report of the Independent Auditors • Unaudited Interim Condensed Consolidated Financial Statements -END- For further information, please contact Press: Vivian Kobeh, Corporate Communications Director +1 786-628-5300 email@example.com Investors: Michel Morin, VP Investor Relations +1 786-628-5270 firstname.lastname@example.org Sarah Inmon, Investor Relations Manager +1-786-628-5303 email@example.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of cable and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around T